Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Slides:



Advertisements
Similar presentations
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
Advertisements

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive to BCL-2 inhibitor. Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive.
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Fig. 8. In vivo suppression of MM by CMLD
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
In vivo efficacy of gemcitabine and MK-1775.
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.
Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.
MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.
Activity of MAC-321 (i. v. and p. o
Effect of MI-773 dosing on long-term efficacy.
IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.
GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.
E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.
NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,
EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,
PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.
The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.
Active AR signaling in enzalutamide-resistant xenograft tumors.
Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.
The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.
PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.
Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.
In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.
Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.
Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)
Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.
A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.
Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).
Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.
A, tumor growth studies in H1975 tumor–bearing mice.
CRA inhibits the growth of human tumor xenografts in vivo.
NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.
Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.
Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.
Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.
Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.
The effect of TGFβ on the post-RT increase of Tregs in tumors.
PDL192 and inhibit the growth of xenograft tumors.
Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.
W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.
Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.
BV6 increases bone metastasis.
CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.
Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.
PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.
In vivo effect of KIN-193 on PTEN-deficient tumors.
MSCs elicit EMT, invasion of carcinoma cells, and increased tumor initiation of xenografts. MSCs elicit EMT, invasion of carcinoma cells, and increased.
Curative effect of W+T treatment in vivo.
Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.
DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.
Presentation transcript:

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. A, SCID mice bearing H3122 xenografts (n = 7 per group) were i.v. dosed with 50 mg/kg ganetespib once weekly, or on a weekly regimen of 2-consecutive-day dosing at 25 mg/kg, as indicated, for 3 weeks. %T/C values are indicated to the right of each growth curve, and the error bars represent the SEM. B, SCID mice bearing H3122 xenografts (n = 7 per group) were orally (p.o.) dosed with 50 mg/kg crizotinib 5×/wk over a 3-week cycle. C, representative images of tumors from vehicle-, ganetespib (2×/wk)–, or crizotinib (50 mg/kg)–treated animals at day 50. D, pharmacodynamic analysis of client protein modulation in H3122 xenografts. SCID mice bearing established H3122 tumors were treated with vehicle or a single bolus injection of ganetespib at 50 mg/kg at the indicated time points between 24 and 96 hours. Mice were also treated with a single bolus injection of crizotinib (50 mg/kg) for 24 hours. Tumors were resected and the levels of the indicated proteins determined by immunoblotting. E, Kaplan–Meier analysis of overall survival in the H3122 xenograft model. Beginning 12 days after tumor cell implantation, SCID mice bearing H3122 xenografts (n = 7 per group) were dosed with vehicle, 50 mg/kg ganetespib 1×/wk i.v, or 50 mg/kg crizotinib 5×/wk orally, and animal survival was monitored until day 75. Jim Sang et al. Cancer Discovery 2013;3:430-443 ©2013 by American Association for Cancer Research